Xencor Inc

NASDAQ:XNCRUnited States

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Contact Information

Headquarters

465 N. HALSTEAD ST., SUITE 200PASADENA, CA, United States 91107

Phone

626-305-5900

Fax

626-305-0350

Executives

President, Chief Executive Officer, Founder and Director

Bassil Dahiyat

Chief Financial Officer, Senior Vice President

Bart Cornelissen

Executive Vice President - Research, Chief Scientific Officer

John Desjarlais

Executive Vice President, Chief Development Officer

Nancy Valente

Senior Vice President, General Counsel, Company Secretary

Celia Eckert